Cold Spring Harbor Laboratory Joins the Illumina Genome Network
News May 28, 2012
Illumina, Inc. has announced that the Cold Spring Harbor Laboratory (CSHL) has joined the Illumina Genome Network (IGN) to provide researchers with broader access to whole genome sequencing (WGS) services.
IGN and CSHL will work in collaboration to bring together CSHL’s expertise in molecular biology and cancer genomics with Illumina’s industry-leading sequencing technology.
“We welcome the distinguished Cold Spring Harbor Laboratory to our prestigious group of IGN partners, and are excited to expand opportunities for deep scientific collaboration,” said Christian Henry, Senior Vice President and General Manager of Illumina’s Genomic Solutions Business.
Henry continued, “Through the Illumina Genome Network, we believe we can speed discovery in areas where CSHL excels, including approaches to understanding tumor development, progression and therapeutic response.”
“The goal of our work at the Cold Spring Harbor Laboratory is to apply our research on basic biological mechanisms to improve the diagnosis and treatment of cancer, as well as neurological disorders and other diseases,” said Richard McCombie, Professor, Cold Spring Harbor Laboratory.
McCombie continued, “By participating in IGN, we are enriching the capabilities of researchers as they strive to solve biology’s most challenging problems.”
IGN links researchers needing large-scale, whole human genome sequencing with world class institutions that provide this service, and delivers unmatched access to the highest quality of whole genome sequencing data.
All IGN partners are experienced and well-published using Illumina TruSeq™ technology, and have completed Illumina’s Certified Service Provider (CSPro) certification.
Each possesses ten or more Illumina sequencing systems (HiSeq 2000 systems and/or Genome Analyzers), providing the scalability to handle large sequencing projects with rapid completion times.
CSHL joins six IGN partners who provide a full range of WGS services:
• The Broad Institute in Cambridge, Massachusetts
• British Columbia Cancer Agency in Vancouver, Canada
• University of Washington Department of Genome Sciences in Seattle, Washington
• National Center for Genome Resources in Santa Fe, New Mexico
• Macrogen & Genomic Medicine Institute in Seoul, Korea
• Illumina’s FastTrack Services lab in San Diego, California
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE